McPhadden Samac Tuovi LLP

McPhadden Samac Tuovi LLP

February 06, 2015 13:31 ET

McPhadden Samac Tuovi LLP Commences Xarelto Class Action Against Bayer and Janssen

TORONTO, ONTARIO--(Marketwired - Feb. 6, 2015) - Toronto law firm McPhadden Samac Tuovi LLP announced today that it has commenced a Xarelto class action law suit. The defendants are Johnson & Johnson and Bayer companies. Xarelto was developed, is marketed and manufactured by Bayer and Janssen, a subsidiary of Johnson & Johnson. The lawsuit has been filed in the Alberta Court of Queen's Bench.

Xarelto is an anticoagulant. It was first approved in Canada for venous thromboembolism (VTE) in 2008 and in 2012 was approved for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Since its introduction, Xarelto has been prescribed to millions of people in Canada and around the world.

The legal proceeding alleges that the defendants failed to adequately warn of the lack of a way to reverse the anticoagulant of Xarelto. Should a patient on Xarelto suffer a bleeding event, excessive bleeding may result because of Xarelto's irreversible anticoagulant effects. In extreme cases, the patient can bleed to death.

Xarelto is intended as a replacement for warfarin, a blood thinner in use for decades. Patients on warfarin require frequent monitoring by health care professionals. Xarelto is promoted as not requiring routine monitoring. The law suit challenges those claims.

The plaintiff lives near London, Ontario and suffered her severe bleeding event while residing in Alberta. The lawsuit is on behalf of all residents of Canada who suffered personal injury as a consequence of an excessive bleeding event while taking Xarelto.

As the legal proceeding was just commenced, the defendants have not yet been served with the claim and the allegations identified above have not been proven in court.

Contact Information

  • Bryan C. McPhadden
    McPhadden Samac Tuovi LLP
    416-601-1020
    416-601-1721 (FAX)
    bmcphadden@mcst.ca